Supporting data for “High-resolution profiles of dynamic antibody responses to SARS-CoV-2 and autoantigens”

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicit antibody response in most patients within three weeks of symptom onset. While SARS-CoV-2 infection result in protective antibodies, other potential pathogenic antibodies can also be generated, resulting in pathogenic inflammatory responses in both the acute phase and long COVID-19. In this project, we established a sequence-linked immunosorbent assay (SLISA) to comprehensively investigate the target specificity and temporal dynamics of antibody responses in COVID-19 patients against SARS-CoV-2 on the genomic scale. Furthermore, by examining antibody response to 1164 known autoantigens, we found that COVID-19 induced antibodies against cellular proteins related to neurological, immunological, and coagulation functions. Some autoantibodies can stimulate T cells in a CD3-dependent manner. Using SLISA, we demonstrated the continuous change in antibody responses against viral- and auto-antigens during the acute and convalescent phases of COVID-19. The platform can be broadly applicable to systematically investigating antibody responses in many physiological and pathological conditions. This is the supporting data set for "High-resolution profiles of dynamic antibody responses to SARS-CoV-2 and autoantigens". It contains relevent raw and processed data for this project, including gel electrophoresis images, PCR data, luminex and elisa data, SLISA analysis, etc.